SPH5030 not checked
Shanghai Pharmaceuticals Holding Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
- Main trialPhase 2
- “To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.”In the company’s words, NCT06434597 on ClinicalTrials.gov
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2026 | A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | |
| Phase 1Completed | 25 Mar 2024 | A Food Effect Study of SPH5030 Tablets. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026